论文部分内容阅读
目的:证实“消渴和胃”方可有效缓解糖尿病鼠胃轻瘫,促进胃排空,并初步探讨其作用机制。方法:110只实验鼠随机分成四组:对照组20只,糖尿病+中药组30只,糖尿病+胃复安组30只,单纯糖尿病组30只。饲养12周后,观察以下项目:①13C呼气实验法测定胃内固体半排空时间;②胃内残留甲基橙液体量;③胃壁肌间神经丛数;④胃壁平滑肌厚度。结果:①与对照组比较,糖尿病鼠的胃壁肌间神经丛数明显减少,平滑肌厚度明显变薄,固体及液体的排空时间明显延长;②给予中药或胃复安治疗可明显改善糖尿病鼠的胃排空速度(P<0.01,P<0.05);③中药组胃壁神经丛数及平滑肌厚度均高于胃复安组(P<0.01,P<0.05),对糖尿病鼠胃固体排空的改善效果优于胃复安组(P<0.05)。结论:“消渴和胃方”可有效促进糖尿病鼠胃动力,固体排空效果优于传统全胃肠动力药胃复安,为糖尿病胃轻瘫提供了新的治疗途径。
Objective: To prove that “diabetes and stomach” can effectively relieve the gastroparesis of diabetic rats, promote gastric emptying, and preliminary explore its mechanism of action. METHODS: One hundred and ten experimental mice were randomly divided into four groups: 20 in the control group, 30 in the diabetes + Chinese medicine group, 30 in the diabetes + metoclopramide group, and 30 in the simple diabetes group. After 12 weeks of feeding, the following items were observed: 113C breath test method to determine the solid half emptying time in the stomach; 2 the amount of liquid methyl orange residue in the stomach; 3 the number of intermuscular nerve bundles in the stomach wall; 4 smooth muscle thickness of the stomach wall. RESULTS: 1Compared with the control group, the number of myenteric plexuses in the stomach wall of diabetic rats was significantly reduced, the thickness of smooth muscles was significantly thinner, and the emptying time of solids and liquids was significantly prolonged; 2 The administration of Chinese herbs or metoclopramide can significantly improve the diabetic rats Gastric emptying rate (P<0.01, P<0.05); 3 The number of plexus in the gastric wall and smooth muscle thickness in the traditional Chinese medicine group were higher than those in the Weifuan group (P<0.01, P<0.05), and the gastric solid emptying of the diabetic rats was improved. The effect was better than that of the metoclopramide group (P<0.05). Conclusion: Xiaokeheweifang can effectively promote the gastric motility of diabetic mice, and the solid emptying effect is better than the traditional total gastrointestinal motility drug metoclopramide, providing a new therapeutic approach for diabetic gastroparesis.